Please try another search
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Name | Age | Since | Title |
---|---|---|---|
Susan M. Mahony | 59 | 2019 | Lead Independent Director |
Troy M. Cox | 59 | 2019 | Independent Director |
Kelvin M. Neu | 50 | 2020 | Independent Director |
Hollings C. Renton | 77 | 2017 | Independent Director |
Derek John Michael Miller | 52 | 2023 | Independent Director |
Carlos E. Campoy | 58 | 2023 | Independent Director |
Nancy E. Davidson | 73 | 2023 | Independent Director |
Alessandra Cesano | 63 | 2024 | Independent Director |
Scott Platshon | 32 | 2024 | Independent Director |
Neil Gallagher | 60 | 2024 | Director |
Kenneth H. Galbraith | 61 | 2022 | Chairman, CEO & Interim CFO |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review